“Safety profile of the latest biotechnologies drugs”
The infiammatory bowel diseases are diseases of unknown etiology without a definitive cure. Patients with IBD, however, can be treated chronically with anti-inflammatory drugs of various type with the aim of maintaining a state of longest possible remission. Most of these drugs are used for a long time and these know well both the therapeutic effects and adverse events.
In recent years new agents developed by biotechnologies consisting of monoclonal antibodies against molecules responsible at various levels of the inflammatory process, have been introduced in clinical practice.
The purpose of our study is to oversee the security of Vedolizumab, the new agent directed against biotechnology integrins, in clinical practice and to compare the safety profile to that of the previous monoclonal antibodies against TNF-α.
This job comes from a partnership with Science Magazine and